Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.61 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.61 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.61 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.61 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 3/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776603 | 0.85 | KMT2A (0.60) | CACNA2D1CACNB1CACNA1BCACNA1CDPP8 | |
| SCHEMBL4779245 | 0.85 | SIGMAR1 (0.55) | DPP4DPP7DPP8DPP9KMT2A | |
| SCHEMBL4776988 | 0.84 | HDAC8 (0.60) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4774397 | 0.84 | KMT2A (0.53) | CACNA2D1CACNB1CACNA1BCACNA1CDPP8 | |
| SCHEMBL7391223 | 0.80 | DPP8 (0.62) | CACNA2D1CACNB1CACNA1BCACNA1CDPP4 | |
| SCHEMBL4776945 | 0.80 | DPP8 (0.59) | CACNA2D1CACNB1CACNA1BCACNA1CDPP4 | |
| SCHEMBL7391221 | 0.80 | DPP8 (0.62) | CACNA2D1CACNB1CACNA1BCACNA1CDPP4 | |
| SCHEMBL4775817 | 0.79 | CACNA2D1 (0.54) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4778274 | 0.78 | DPP4 (0.61) | CACNA2D1CACNB1CACNA1BCACNA1CDPP4 | |
| SCHEMBL4779237 | 0.78 | FAAH (0.54) | DPP4DPP7DPP8DPP9TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | CACNA2D1 4234/4885CACNB1 2893/4885CACNA1B 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.